News
02-28-2014, 03:39 AM
Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.
More... (http://www.news-medical.net/news/20140228/Celsion-reports-positive-interim-data-from-Phase-2-DIGNITY-Trial-of-ThermoDox-in-RCWBC.aspx)
More... (http://www.news-medical.net/news/20140228/Celsion-reports-positive-interim-data-from-Phase-2-DIGNITY-Trial-of-ThermoDox-in-RCWBC.aspx)